Glaukos (GKOS) Set to Announce Quarterly Earnings on Wednesday

Glaukos (NYSE:GKOS) will be posting its quarterly earnings results after the market closes on Wednesday, February 28th.

Shares of Glaukos (GKOS) opened at $31.23 on Wednesday. The firm has a market cap of $1,073.95, a price-to-earnings ratio of -780.55, a price-to-earnings-growth ratio of 45.03 and a beta of 1.21. Glaukos has a 12 month low of $23.08 and a 12 month high of $52.49.

A number of equities research analysts have weighed in on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Cantor Fitzgerald set a $48.00 price objective on shares of Glaukos and gave the company a “buy” rating in a research report on Wednesday, January 10th. Zacks Investment Research downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 13th. ValuEngine downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Monday, February 5th. Finally, Stephens reissued an “overweight” rating and set a $40.00 price objective (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $44.86.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Earnings History for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with's FREE daily email newsletter.

Leave a Reply